Compare Coursera Inc (COUR) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Johnson & Johnson — how do they compare? Coursera Inc trades at $5.2 (market cap $1.39B), while Johnson & Johnson trades at $261.43 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 444.7× Coursera Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Coursera Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Johnson & Johnson for 129 Days on average.
| COUR | JNJ | |
|---|---|---|
Market Cap | $1.39B | $618.09B |
Volume | 9,728,980 | 6,050,983 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $278.43 |
52-Week Low | $4.64 | $186.00 |
Typical Hold Time | 47 Days | 129 Days |
Enterprise Value | $648.49M | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.16, up 0.98% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company shows improving revenue growth from $524M in 2022 to $758M in 2025, though it remains unprofitable with a -15.39% net margin. Recent news highlights strong institutional interest with Deutsche Bank acquiring 1.7M shares and positive analyst sentiment with 52.94% buy ratings.
The stock presents a growth opportunity with 44% subscriber growth and $85M synergy targets, but faces execution risks from ongoing losses and competitive pressures. With a consensus price target of $7.40 representing 43% upside, the bullish analyst outlook contrasts with fundamental profitability challenges that require careful monitoring.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
